Evidence map›Paper›PMID 27757226›Full record

ReviewClinical & translational immunology2016

The microbiota and chronic kidney diseases: a double-edged sword.

Raphael Jose Ferreira Felizardo, Angela Castoldi, Vinicius Andrade-Oliveira, Niels Olsen Saraiva Câmara

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinical & translational immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04361097 (Fecal Microbiota Transplantation as a Therapeutic Strategy in the Progression of Chronic Kidney Disease), which is not on this map. Cited by 41 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04361097 nacompletednot on this mapstarted 2018, after this paper: background citation

Fecal Microbiota Transplantation as a Therapeutic Strategy in the Progression of Chronic Kidney Disease

TypeinterventionalSponsorHospital Universitario Dr. Jose E. GonzalezRan2018 to 2020Enrolled28ConditionsChronic Kidney Disease Due to Hypertension, Chronic Kidney Disease Due to Type 2 Diabetes MellitusArmsFaecal microbiota transplant, Placebo
3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Review
  6. Review
  7. Article
  8. The impact of progressive chronic kidney disease on hepatic drug metabolism.Drug metabolism and disposition: the biological fate of chemicals · 2025
    Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Raphael Jose Ferreira FelizardoLaboratory of Clinical and Experimental Immunology, Nephrology Division, Federal University of São Paulo , São Paulo, Brazil.
Angela CastoldiDepartment of Immunology, Laboratory of Transplantation Immunobiology, Institute of Biomedical Sciences IV, University of São Paulo , São Paulo, Brazil.
Vinicius Andrade-OliveiraDepartment of Immunology, Laboratory of Transplantation Immunobiology, Institute of Biomedical Sciences IV, University of São Paulo , São Paulo, Brazil.
Niels Olsen Saraiva CâmaraLaboratory of Clinical and Experimental Immunology, Nephrology Division, Federal University of São Paulo, São Paulo, Brazil; Department of Immunology, Laboratory of Transplantation Immunobiology, Institute of Biomedical Sciences IV, University of São Paulo, São Paulo, Brazil; Department of Medicine, Laboratory of Renal Physiology (LIM 16), University of São Paulo, São Paulo, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent findings regarding the influence of the microbiota in many inflammatory processes have provided a new way to treat diseases. Now, one may hypothesize that the origin of a plethora of diseases is related to the health of the gut microbiota and its delicate, although complex, interface with the epithelial and immune systems. The 'westernization' of diets, for example, is associated with alterations in the gut microbiota. Such alterations have been found to correlate directly with the increased incidence of diabetes and hypertension, the main causes of chronic kidney diseases (CKDs), which, in turn, have a high estimated prevalence. Indeed, data have arisen showing that the progression of kidney diseases is strictly related to the composition of the microbiota. Alterations in the gut microbiota diversity during CKDs do not only have the potential to exacerbate renal injury but may also contribute to the development of associated comorbidities, such as cardiovascular diseases and insulin resistance. In this review, we discuss how dysbiosis through alterations in the gut barrier and the consequent activation of immune system could intensify the progression of CKD and vice versa, how CKDs can modify the gut microbiota diversity and abundance.

Identifiers

PMID27757226
PMCPMC5067952

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.